In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)

Annals of Oncology

Volumn 9, Issue 9, 1998, Pages 989-993

  Ghielmini, M ^a   Colli, E ^a   Erba, E ^c   Bergamaschi, D ^c   Pampallona, S ^d   Jimeno, J ^b   Faircloth, G ^b   Sessa, C ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b PHARMAMAR S A   (Spain)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d ForMed   (Switzerland)

Author keywords

Cell lines; Ecteinascidin; Hematotoxicology; In vitro assays

Indexed keywords

GROWTH FACTOR; TRABECTEDIN;

ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CELL CULTURE; CANCER RESEARCH; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MELANOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0031733644     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008430827281     Document Type: Article

References (21)

1. Cragg GM, Newman DJ, Weiss RB. Coral reefs, forests, and thermal vents: The worldwide exploration of nature for novel antitumor agents. Semin Oncol 1997; 24: 156-163.
2. Moore BM, Seaman FC, Hurley LH. NMR-based model of an Ecleinascidin 743-DNA adduct. J Am Chem Soc 1997; 119: 5475 5476.
3. Izbicka E, Lawrence R, Davidson K et al. Incomplete cross-resistance between Ecteinascidin 743 (ET-743) and standard chemotherapeutic agents against primary tumors in human tumor cloning assay. Ann Oncol 1998; 9 (Suppl 2): 34.
4. Eckhardt SG, Degen D, Ortiz V et al. In vitro studies of a novel marine cytotoxic, Ecteinascidin (ET-743). Ann Oncol 1996; 7 (Suppl 5): 131.
5. Faircloth G, Hendricks HR, Giavazzi R et al. In vivo antitumor activity of Ecteinascidin 743 (ET-743), a novel marine derived cytotoxic against human xenografts tumor models. Ann Oncol 1996; 7 (Suppl 5): 125.
6. Valoti G, Nicoletti MI, Faircloth G et al. Antitumor effect of Ecteinascidin 743 (ET-743) on human ovarian carcinoma xenografts. Proc Am Assoc Cancer Res 1997; 38: 219.
7. Jimeno JM, Faircloth G, Cameron L et al. Progress in the acquisition of new marine-derived anticancer compounds: Development of Ecteinascidin 743 (ET-743). Drugs Fut 1996; 21: 1155-65.
8. Pommier Y, Kohlhagen G, Bailly C et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by Ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996; 35: 13303 9.
9. Garcia-Rocha M, Garica-Gravalos MD, Avila J. Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: Ecteinascidin 743, Isohomohalichondrin-B and LL-15. Br J Cancer 1996; 73: 875-83.
10. Mantovani L, La Valle E, Bonfanti M et al. Effect of Ecteinascidin 743 (ET-743) on the interaction between transcription factors and DNA. Ann Oncol 1998; 9 (Suppl 2): 139.
11. Léglise MC, Darodes de Tailly P, Vignot JL et al. A cellular model for drug interactions on hematopoiesis: The use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression. Cell Biology and Toxicology 1996; 12: 39-53.
12. Ghielmini M, Bosshard G, Capolongo L et al. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer 1997; 75: 878-83.
13. Ghielmini M, Colli E, Bosshard G et al. Hematotoxicity on human bone marrow and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyl-doxorubicin and its metabolites. Cancer Chemolher Pharmacol 1998; 42: 235-40.
14. Coutinho LH, Gilleece MH, De Wynter EA et al. Clonal and long-term cultures using human bone marrow. In Testa NG and Molineux G (eds): Haemopoiesis. A Practical Approach. New York: Oxford University Press 1993; 75-105.
15. Lewis JL, Blackett NM, Gordon MY. The kinetics of colony formation by CFU-GM in vitro. Br J Haematol 1994; 88: 440-2.
16. Eckhardt SG, Degen D, Faircloth GT et al. Activity of Ecteinascidin, a novel marine cytotoxic. against primary human tumor colony-forming units. Proc Am Assoc Cancer Res 1996; 37: 409.
17. Bowman A, Twelves C, Hoekman K et al. Phase I clinical and pharmacokinetic (PK) study of Ecteinascidin 743 (ET-743) given as a one-hour infusion every 21 days. Ann Oncol 1998; 9 (Suppl 2): 118.
18. Villalona-Calero M, Eckardt SG, Weiss G et al. A phase I and pharmacokinetic study of ET-743, a novel DNA minor groove binder of marine origin, administered as a one-hour infusion daily × 5 days. Ann Oncol 1998; 9 (Suppl 2): 118.
19. Cvitkovic E, Mekranter B, Taamma A et al. Ecteinascidin 743 (ET-743) 24-hour continuous intravenous infusion phase I study in solid tumour patients. Ann Oncol 1998; 9 (Suppl 2): 119.
20. Naughton BA, Sibanda B, Azar L, San Roman J. Differential effects of drugs upon hematopoiesis can be assessed in long-term bone marrow cultures established on nylon screens. PSEBM 1992; 199: 481-90.
21. Volpe DA, Du D, Grieshaber CK, Murphy MJJ. In vitro characterisation of the myelotoxicity of cyclopentenyl cytosine. Cancer Chemother Pharmacol 1994; 34: 103 8.